This collateral signaling pathway then paradoxically leads to increased cancer cell growth in FGFR1 amplified cells treated with FGFR1 inhibitors and highlights a challenge of FGFR inhibitor use in cancer treatment. The gene discussed is FGFR1; the disease is cancer.